Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial..
Diabetes Obes Metab. 19(12), 1805-1809.
(2017). Novel Advances in the Association Between Helicobacter pylori Infection, Metabolic Syndrome, and Related Morbidity..
Helicobacter. 20(6), 405-9.
(2015). Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone..
Osteoporos Int. 22(1), 363-7.
(2011). Paget's disease of bone: emphasis on treatment with zoledronic acid..
Expert Rev Endocrinol Metab. 4(5), 423-434.
(2009). Adipokines in nonalcoholic fatty liver disease..
Metabolism. 65(8), 1062-79.
(2016). Selenium and selenoprotein P in nonalcoholic fatty liver disease..
Hormones (Athens). 19(1), 61-72.
(2020). Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications..
Hepatobiliary Pancreat Dis Int.
(2023). Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis..
Curr Med Chem.
(2023). Visual vignette. Anaplastic thyroid carcinoma..
Endocr Pract. 18(1), 108.
(2012). Homocysteine in nonalcoholic steatohepatitis: A reply..
Eur J Intern Med. 35, e40-e41.
(2016). Serum alpha-fetoprotein in patients with nonalcoholic fatty liver disease..
Eur Rev Med Pharmacol Sci. 17(17), 2411-2.
(2013). Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis..
Metabolism. 60(3), 313-26.
(2011). Insulin resistance and therapy: cross-talk between phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways..
Med Hypotheses. 72(5), 610.
(2009). Nonlinear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis..
J Clin Gastroenterol. 44(3), 229-30; author reply 230-1.
(2010). Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement..
Metabolism. 96, 66-82.
(2019). Aromatase inhibitors in post-menopausal endometriosis..
Reprod Biol Endocrinol. 9, 90.
(2011). Periostin on the road to nonalcoholic fatty liver disease..
Endocrine. 51(1), 4-6.
(2016). Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index..
Ann Hepatol. 12(5), 749-57.
(2013). Systematic review of cases reporting blood extravasation-related complications after thyroid fine-needle biopsy..
J Otolaryngol Head Neck Surg. 39(5), 532-41.
(2010). Helicobacter pylori infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy..
Helicobacter. 24(3), e12588.
(2019). Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort..
Horm Metab Res. 51(2), 134-140.
(2019). Leptin in health and disease: facts and expectations at its twentieth anniversary..
Metabolism. 64(1), 5-12.
(2015). The use of demographic, ultrasonographic and scintigraphic data in the diagnostic approach of thyroid nodules..
Exp Clin Endocrinol Diabetes. 117(4), 159-64.
(2009). Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease..
Curr Pharm Des. 29(41), 3263-3265.
(2023).
(2016).